These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 38625582)

  • 1. Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.
    Sacco S; Foschi M; Ornello R; De Santis F; Pofi R; Romoli M
    Diabetologia; 2024 Jul; 67(7):1192-1205. PubMed ID: 38625582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
    Benn M; Emanuelsson F; Tybjærg-Hansen A; Nordestgaard BG
    Diabetologia; 2021 Jul; 64(7):1492-1503. PubMed ID: 33765180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is management of hyperglycaemia in acute phase stroke still a dilemma?
    Savopoulos C; Kaiafa G; Kanellos I; Fountouki A; Theofanidis D; Hatzitolios AI
    J Endocrinol Invest; 2017 May; 40(5):457-462. PubMed ID: 27873213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Serowik TC; Pantalone KM
    J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.
    Aroda VR; Eckel RH
    Diabetes Obes Metab; 2022 Dec; 24(12):2297-2308. PubMed ID: 35929480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes, hyperglycaemia, and acute ischaemic stroke.
    Luitse MJ; Biessels GJ; Rutten GE; Kappelle LJ
    Lancet Neurol; 2012 Mar; 11(3):261-71. PubMed ID: 22341034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.
    McGrath RT; Hocking SL; Priglinger M; Day S; Herkes GK; Krause M; Fulcher GR
    BMJ Open; 2016 Feb; 6(2):e008203. PubMed ID: 26911582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: "INSIST" study.
    Mohammedi K; Fauchier L; Quignot N; Khachatryan A; Banon T; Kapnang R; Kikuchi K; Ren H; Massien C; Vigié L; Larsen S; Sibon I
    Cardiovasc Diabetol; 2024 May; 23(1):183. PubMed ID: 38812009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin for glycaemic control in acute ischaemic stroke.
    Bellolio MF; Gilmore RM; Ganti L
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005346. PubMed ID: 24453023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2.
    Maranta F; Cianfanelli L; Cianflone D
    Adv Exp Med Biol; 2021; 1307():129-152. PubMed ID: 32266607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
    Lim S; Oh TJ; Dawson J; Sattar N
    Diabetes Obes Metab; 2020 Jan; 22(1):6-15. PubMed ID: 31379119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose targets for preventing diabetic kidney disease and its progression.
    Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugar and stroke: cerebrovascular disease and blood glucose control.
    Quinn TJ; Dawson J; Walters MR
    Cardiovasc Ther; 2011 Dec; 29(6):e31-42. PubMed ID: 20491782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.